Assessing difference in the tumor and immune microenvironment of BRCA1/2 mutated versus BRCA wild type high grade serous ovarian cancers

被引：0
|
作者：
Qian, Jing
Roman, Lynda D.
Rajpara, Seeta
Neuman, Monica
Khetan, Varun
Craig, David W.
Carlson, Joseph
Carpten, John D.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6082
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Investigating the Tumor Immune Microenvironment in BRCA1 and BRCA2-Associated and Basal Breast Carcinomas
    Virine, Boris
    Pinnaduwage, Dushanthi
    Mulligan, Anna Marie
    Jackson, Hartland
    Andrulis, Irene
    Williams, Phillip
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1568 - S1568
  • [22] Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas
    Kramer, C. J. H.
    Lanjouw, L.
    Ruano, D.
    ter Elst, A.
    Santandrea, G.
    Solleveld-Westerink, N.
    Werner, N.
    van Der Hout, A. H.
    de Kroon, C. D.
    van Wezel, T.
    Berger, L. P., V
    Jalving, M.
    Wesseling, J.
    Smit, V. T. H. B. M.
    de Bock, G. H.
    van Asperen, C. J.
    Mourits, M. J. E.
    Vreeswijk, M. P. G.
    Bart, J.
    Bosse, T.
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 137 - 146
  • [23] GENOMICS OF BRCA1/2-MUTATED BREAST CANCERS
    Jonkers, J.
    CELLULAR ONCOLOGY, 2010, 32 (03) : 162 - 162
  • [24] Comparative study between patients with mutated BRCA1 2 breast and or ovarian cancer and non-mutated BRCA1 2
    Habak, N.
    Abdellah, M. Ait
    Chikouche, A.
    Griene, L.
    CLINICA CHIMICA ACTA, 2024, 558
  • [25] BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
    McAlpine, Jessica N.
    Porter, Henry
    Koebel, Martin
    Nelson, Brad H.
    Prentice, Leah M.
    Kalloger, Steve E.
    Senz, Janine
    Milne, Katy
    Ding, Jiarui
    Shah, Sohrab P.
    Huntsman, David G.
    Gilks, C. Blake
    MODERN PATHOLOGY, 2012, 25 (05) : 740 - 750
  • [26] MicroRNA profiling to identify novel determinants of platinum resistance in BRCA1/2-mutated high-grade serous ovarian cancer
    Meghani, Khyati
    Gogola, Ewa
    Rottenberg, Sven
    Jonkers, Jos
    Matulonis, Ursula
    Swisher, Elizabeth
    Konstantinopoulos, Panagiotis
    Chowdhury, Dipanjan
    CANCER RESEARCH, 2017, 77
  • [27] Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system
    McCuaig, Jeanna M.
    Care, Melanie
    Ferguson, Sarah E.
    Kim, Raymond H.
    Stockley, Tracy L.
    Metcalfe, Kelly A.
    GYNECOLOGIC ONCOLOGY, 2020, 158 (03) : 747 - 753
  • [28] BRCA1/2 reversion mutations as a mechanism of acquired drug resistance in BRCA1/2-mutated cancers
    Taniguchi, Toshiyasu
    CANCER SCIENCE, 2023, 114 : 260 - 260
  • [29] The tumor immune microenvironment of germline BRCA1/2 and sporadic prostate cancer
    Trigos, Anna S.
    Pasam, Anupama
    Banks, Patricia Diana
    Wallace, Roslyn
    Keam, Simon P.
    Thorne, Heather
    Mitchell, Catherine
    Clouston, David
    Murphy, Declan G.
    Lawrentschuk, Nathan
    Bolton, Damien M.
    Moon, Daniel
    Castro, Elena
    Olmos, David
    Darcy, Phillip K.
    Haupt, Ygal
    Williams, Scott
    Goode, David L.
    Neeson, Paul J.
    Sandhu, Shahneen Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] A BRCA 1/2 Mutational Signature in Ovarian High Grade Serous Carcinoma
    Dong, F.
    Davineni, P. K.
    Howitt, B. E.
    Beck, A. H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 988 - 988
12345